Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed elements: a strong product pipeline with FDA approvals and optimistic future revenue growth, but current challenges include negative free cash flow, operating losses, and manufacturing issues. The Q&A highlights stable revenue from existing products and positive feedback on new launches, but also concerns about manufacturing constraints and management's vague responses on key issues. These factors balance each other out, leading to a neutral sentiment.
Key Financial Performance
Revenue for Q4 2025 $8.6 million, a 36% increase compared to $6.3 million in the prior year fourth quarter. The increase was driven by partial revenue recognition on 2 Genesis systems and ancillary devices, as well as initial sales of Stereotaxis MAGiC Sweep catheter in the U.S. and MAGiC catheter in Europe.
System Revenue for Q4 2025 $3.3 million, compared to $1.4 million in the prior year quarter. This reflected partial revenue recognition on 2 Genesis systems and ancillary devices.
Recurring Revenue for Q4 2025 $5.3 million, compared to $9.4 million in the prior year quarter. The growth was driven by initial sales of Stereotaxis MAGiC Sweep catheter in the U.S. and MAGiC catheter in Europe.
Full Year 2025 Revenue $32.4 million, compared to $26.9 million in 2024. The increase was driven by growth in both system and recurring revenue.
Full Year 2025 System Revenue $10.2 million, compared to $8.6 million in the prior year. The increase was attributed to sales of GenesisX systems and ancillary devices.
Full Year 2025 Recurring Revenue $22.2 million, compared to $18.3 million in the prior year. Growth was driven by increased catheter revenue.
Gross Margin for Q4 2025 Approximately 50% of revenue.
Gross Margin for Full Year 2025 53% of revenue. Recurring revenue gross margin was 67%, and system gross margin was 21%. Margins were impacted by acquisition-related accounting and lower initial margins on newly launched devices.
Operating Expenses for Q4 2025 $10 million, including $3 million in noncash charges. Adjusted operating expenses were $7 million.
Operating Expenses for Full Year 2025 $26.3 million, compared with $27 million in the prior year. The decrease was primarily driven by lower general and administrative expenses and the receipt of an employee retention tax credit.
Operating Loss and Net Loss for Q4 2025 $5.6 million and $5.5 million, respectively. Adjusted operating loss and adjusted net loss were $2.6 million and $2.5 million, respectively.
Operating Loss and Net Loss for Full Year 2025 Adjusted operating loss of $9.3 million and adjusted net loss of $8.8 million, compared to $12.4 million and $11.7 million in the prior year. The improvement was due to increased revenue and reduced operating expenses.
Negative Free Cash Flow for Full Year 2025 $13.8 million, compared to $8.5 million in 2024. The increase was driven by a $5.6 million use for working capital in 2025.
Cash and Cash Equivalents as of December 31, 2025 $13.4 million, with no debt.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
GenesisX robot: Achieved regulatory approvals in the United States and Europe. Allows for easier adoption in hospitals with less complexity and cost. First commercial system sold in 2025.
MAGiC Ablation Catheter and MAGiC Sweep Mapping Catheter: Achieved regulatory approvals in the United States and Europe. Contributed hundreds of thousands of dollars in revenue in 2025. Manufacturing ramping up to meet demand.
Synchrony Digital Surgery suite: Received CE Mark and submitted for FDA clearance. Expected to generate over $3 million in revenue in 2026.
EP ablation market: Targeting a $2 billion market opportunity in complex procedures like congenital heart disease and ventricular tachycardia. Market expected to grow to $20 billion by 2030.
Endovascular surgery: Expanding robotics applications beyond EP to interventional cardiology, radiology, and neuro interventions. Submitted regulatory approvals for new guide catheter and guidewire.
Manufacturing improvements: Scaling GenesisX production to one robot every two months and MAGiC catheter production to 500 units per month by year-end 2026.
Revenue growth: Achieved 36% revenue growth in Q4 2025 compared to prior year. Full-year revenue reached $32.4 million, up from $26.9 million in 2024.
Shift in commercial model: Transitioning from outright robot sales to a blend of sales, leases, and disposable commitments. Increasing per-procedure revenue from $1,000 to over $5,000.
Digital and AI integration: Advancing Synchrony and SynX for enhanced workflow and AI capabilities. Expected to add Software-as-a-Service revenue model.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Manufacturing Challenges: Scaling manufacturing of the MAGiC catheter has been difficult, with production only in the dozens per month when hundreds are needed to meet demand. This has led to catheter shortages, particularly in Q4 2025 and early 2026. Efforts to improve production processes are ongoing, but the ramp-up remains a challenge.
Regulatory and Administrative Delays: Post-approval administrative efforts to get products on hospital contracts and through regional registrations have slowed commercialization. This has delayed the ability to fully capitalize on new product launches.
Dependency on Contract Manufacturing: The MAGiC catheter is manufactured by a contract partner, Osypka, in Germany. Challenges in scaling production at Osypka have caused supply shortages, impacting revenue and customer satisfaction.
High Initial Costs for Hospitals: The adoption of robotics has historically been hindered by the high costs and complexity of installation, requiring significant construction and planning. Although efforts are being made to simplify this, it remains a barrier to broader adoption.
Revenue Dependency on New Products: The company’s revenue growth is heavily reliant on the successful commercialization of new products like GenesisX and MAGiC. Any delays or issues in these areas could significantly impact financial performance.
Economic and Financial Risks: The company reported a net loss and negative free cash flow for 2025, with significant cash use for working capital. While efforts are being made to stabilize operating expenses, financial risks remain.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects to deliver double-digit revenue growth in 2026, with annual revenue surpassing $40 million. Quarterly revenue is projected to be below $10 million in the first two quarters and ramp above $10 million in the latter two quarters.
Recurring Revenue Margins: Anticipated increases in production volume of existing devices within the next three years are expected to support recurring revenue margins of over 75% and system margins of over 50%.
GenesisX Robot Commercialization: The company aims to establish at least 5 active GenesisX programs in 2026, with a mix of sales, leases, and placements. Orders may outpace production, and the company plans to demonstrate rapid installation in existing labs.
MAGiC Catheter Manufacturing and Commercialization: The company plans to scale MAGiC catheter manufacturing from 100 units per month to 500 units per month by year-end 2026. Regulatory approval for combining MAGiC with a Pulsed Field Ablation Generator is expected in Europe by year-end.
Expansion into Endovascular Surgery: The company is working on regulatory approval for the EMAGIN 5F guide catheter and EMAGIN .014 guidewire, with the latter expected to be submitted for approval in summer 2026. Two significant strategic efforts are underway to expand robotics into interventional cardiology and neuro interventions.
Digital Surgery Suite Technology: The company expects FDA clearance for Synchrony in the coming weeks and projects over $3 million in revenue from initial demand in 2026. Additional AI features and a Software-as-a-Service revenue model are being developed for Synchrony.
Profitability and Cash Flow: The company expects growing recurring revenue and stable operating expenses to support reduced cash use in 2026 compared to 2025. A working capital benefit to cash flow is also anticipated.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Do you still expect to sell the previous Genesis system alongside the new GenesisX programs?
A:Yes, Genesis sales and orders are expected to continue at a similar pace as in previous years, with mid-single-digit numbers of Genesis systems sold annually, generating approximately $10 million in revenue. This level is expected to remain stable for the next couple of years while ramping up GenesisX.
Q:What is assumed in the $3+ million revenue goal for Synchrony in 2026?
A:The $3+ million revenue goal is based on capital sales of Synchrony systems, with several hospitals expected to standardize their EP labs on Synchrony. Pricing for Synchrony is estimated at $150,000 to $200,000 per system, depending on third-party equipment integration. The revenue goal also includes recurring revenue streams from service contracts and premium software subscriptions.
Q:How are you allocating MAGiC catheters to specific accounts given manufacturing capacity constraints?
A:The allocation process involves working with the commercial team and physicians to manage demand and expectations. Efforts are being made to address administrative items at hospitals in parallel with ramping manufacturing. The goal is to meet demand as manufacturing scales up.
Q:What is the path to launching MAGiC with Pulse Field Ablation in Europe?
A:The compatibility of the MAGiC Catheter with the Centauri PFA generator has been demonstrated through bench and animal testing. The catheter's design and ablation characteristics are similar to existing approved catheters. A dossier has been compiled for EU regulatory review, and approval is expected in the short term.
Q:Can you provide more details on the product mix for the full-year guidance?
A:System revenue is expected to grow with the launch of GenesisX, which will include a mix of sales, leases, and disposable commitments. Most revenue growth will come from disposables, driven by the manufacturing ramp of MAGiC and MAGiC Sweep. Synchrony revenue, estimated at $3 million, will also contribute to capital revenue.
Q:What feedback have you received on the transition to the MAGiC ablation catheter?
A:Feedback has been positive, with customers appreciating the improved navigation capability, stable forces, reduced irrigation, and tip lesion characteristics of MAGiC. However, the transition from the old ecosystem has been challenging due to resistance from the previous partner.
Q:What caused the Q4 revenue to be lower than expected?
A:The primary factors were lower MAGiC catheter manufacturing due to adjustments in the manufacturing process and a slowdown in volume from the transition of J&J's catheter. These issues impacted the ability to meet the $6 million guidance, resulting in $5.3 million reported revenue.
Q:What are the different economic models for GenesisX, and how do you see them evolving?
A:The three core models are outright capital sales, leases, and placements with disposable commitments. The company is agnostic to these models and expects the majority of future capital deals to involve leasing or disposable commitments, similar to Intuitive Surgical's approach.
Q:What are the OpEx plans for 2026, and how will investments be managed?
A:Operating expenses are expected to remain flat, with adjusted OpEx under $30 million annually. Savings from completed projects will be redirected to manufacturing ramp and commercial activities. Significant investments in the commercial team are anticipated in 2027 as catheter revenue grows.
Q:What is the opportunity in China for this year?
A:The first Genesis systems are expected to be sold in China this year, despite macroeconomic challenges. The company also anticipates a shift from the older J&J catheter to MicroPort's catheter, generating royalties. Regulatory submissions for GenesisX and MAGiC in China are also planned.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact revenue recognition for GenesisX systems due to the mix of sales, leases, and disposable commitments. Additionally, they did not provide a clear timeline for resolving manufacturing challenges with MAGiC catheters or the exact milestones for EU approval of MAGiC with Pulse Field Ablation.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
EMAGIN
FDA clearance
MAGiC Sweep
MAGiC catheter
Osypka production
SynX
afternoon
approach
approval hospital
catheter Osypka
catheter month
catheter procedure
change
commercialization effort
commitment
component
connectivity
core
cost
effort MAGiC
effort value
hospital contract
hundred thousand
increase
innovation
lease placement
manufacturing MAGiC
mission
neuro intervention
noncash charge
observation
patient
platform
robotics surgery
sale lease
start
suite
thousand dollar
STXS Transcript
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call presents mixed signals: while there are promising developments like ramping up MAGiC catheter production and GenesisX system expansion, financial performance in Q1 2026 was weak with declining revenues and increased losses. The Q&A reveals confidence in future growth, yet lacks concrete timelines and details, which could cause investor hesitation. Given the absence of a market cap and the mixed sentiment, the stock price is likely to remain stable, resulting in a neutral prediction.
Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript
Unknown3-9
The earnings call reveals mixed elements: a strong product pipeline with FDA approvals and optimistic future revenue growth, but current challenges include negative free cash flow, operating losses, and manufacturing issues. The Q&A highlights stable revenue from existing products and positive feedback on new launches, but also concerns about manufacturing constraints and management's vague responses on key issues. These factors balance each other out, leading to a neutral sentiment.
Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript
Unknown11-11
The earnings call presented mixed signals: while product development with GenesisX and new catheters is promising, financials show consistent losses and a negative cash flow. The Q&A reveals a cautious approach to new launches and regulatory approvals, indicating uncertainty. No strong catalysts like partnerships or guidance changes were mentioned. Therefore, the stock is likely to remain stable in the short term.
Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript
Unknown5-12
The earnings call presents mixed signals: while product development and business updates show promise, especially in Europe, financial performance is concerning with declining system revenue and increasing operating losses. The Q&A reveals positive reception of new products but highlights uncertainties in U.S. regulatory approvals and market adoption challenges. The lack of a share repurchase program and structural challenges further dampen sentiment. Overall, the mixed guidance and financials, coupled with regional uncertainties, suggest a neutral stock price movement.
STXS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
